Special Issue

Innovative Approaches in Drug Design: The Pathway from Molecular Mechanisms to New Therapeutic Interventions

Message from the Guest Editors

The field of drug design is undergoing a transformative phase characterized by the exploration of pioneering strategies that transcend traditional paradigms. At the heart of these innovative actions lies a deep understanding of the molecular foundations of diseases. coupled with the development of sophisticated tools and technologies which, informed by structural biology, computational chemistry, pharmacology, and bioinformatics, are aimed at manipulating these complex biological pathways. The elucidation of threedimensional structures of relevant biomolecules at atomic resolution enables the precise targeting of specific molecular targets implicated in disease progression. In this Special Issue, we welcome articles dealing with all aspects of drug design research, from basic to clinical studies, and invite scientists and drug specialists to publish their original research works, review articles, and communications on this wide health domain.

Guest Editors

Dr. Cristina Manuela Dragoi

Dr. Alina Crenguta Nicolae

Dr. Ion-Bogdan Dumitrescu

Deadline for manuscript submissions

closed (20 January 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/196343

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).